Tag Archives: MEI Pharma

MEI Pharma (MEIP) Receives a Buy from LifeSci Capital

In a report issued on July 2, Adam Evertts PhD from LifeSci Capital maintained a Buy rating on MEI Pharma (MEIP – Research Report), with a price target of $9.00. The company’s shares closed last Thursday at $3.49. PhD has

LifeSci Capital Believes MEI Pharma (NASDAQ: MEIP) Still Has Room to Grow

LifeSci Capital analyst Adam Evertts PhD maintained a Buy rating on MEI Pharma (MEIP – Research Report) on June 19 and set a price target of $9.00. The company’s shares closed last Friday at $3.99, close to its 52-week high

Wells Fargo Reiterates Overweight on MEI Pharma Shares, Sees 272% Upside For The Stock

In a research report released on Tuesday, Wells Fargo analyst Jim Birchenough reiterated an Overweight rating on MEI Pharma (NASDAQ:MEIP)with a price target of $13, which implies an upside of 272% from current levels. According to TipRanks.com, which measures analysts’

JonesTrading Believes MEI Pharma (NASDAQ: MEIP) Won’t Stop Here

In a report released today, Matthew Cross from JonesTrading maintained a Buy rating on MEI Pharma (MEIP – Research Report), with a price target of $9.00. The company’s shares closed last Tuesday at $3.91, close to its 52-week high of

Analysts Offer Insights on Healthcare Companies: MEI Pharma (NASDAQ: MEIP) and Sanofi (Other OTC: SNYNF)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on MEI Pharma (MEIP – Research Report) and Sanofi (SNYNF – Research Report) with bullish sentiments. MEI Pharma (MEIP) According to TipRanks.com, Cross

MEI Pharma (MEIP) Gets a Buy Rating from H.C. Wainwright

H.C. Wainwright analyst Andrew Fein maintained a Buy rating on MEI Pharma (MEIP – Research Report) today and set a price target of $10.00. The company’s shares closed last Monday at $2.40. According to TipRanks.com, Fein is a 5-star analyst